To complete our library of publications from Panaxea’s researchers we’d like to offer you a compilation of all the publications between 2012 and 2017.

Please use the search button in the top right corner on this website if you are looking for specific publications or send us an email if you have any questions regarding publications or the expertise and services we offer, via info@panaxea.eu

2017

Value of Implementation of Strategies to Increase the Adherence of Health Professionals and Cancer Survivors to Guideline-Based Physical Exercise.
Mewes JC, Steuten LMG, IJsbrandy C, IJzerman MJ, van Harten WH.
Value Health. 2017 Dec
https://www.ncbi.nlm.nih.gov/pubmed/29241893

A SYSTEMATIC APPROACH FOR ASSESSING, IN THE ABSENCE OF FULL EVIDENCE, WHETHER MULTICOMPONENT INTERVENTIONS CAN BE MORE COST-EFFECTIVE THAN SINGLE COMPONENT INTERVENTIONS.
Mewes JC, Steuten LMG, IJzerman MJ, van Harten WH.
Int J Technol Assess Health Care. 2017 Jan
https://www.ncbi.nlm.nih.gov/pubmed/28889817

2015

Return-to-work intervention for cancer survivors: budget impact and allocation of costs and returns in the Netherlands and six major EU-countries.
Mewes JC, Steuten LM, Groeneveld IF, de Boer AG, Frings-Dresen MH, IJzerman MJ, van Harten WH.
BMC Cancer. 2015 Nov 12
https://www.ncbi.nlm.nih.gov/pubmed/26560707

Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients.
Mewes JC, Steuten LM, Duijts SF, Oldenburg HS, van Beurden M, Stuiver MM, Hunter MS, Kieffer JM, van Harten WH, Aaronson NK.
J Cancer Surviv. 2015 Mar
https://www.ncbi.nlm.nih.gov/pubmed/25179578 

Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: insights from 2-year follow-up of the TWENTE trial.
Lam MK, Sen H, Tandjung K, Löwik MM, Basalus MW, Mewes JC, Stoel MG, van Houwelingen KG, Linssen GC, Ijzerman MJ, Doggen CJ, von Birgelen C.
Catheter Cardiovasc Interv. 2015 Mar
https://www.ncbi.nlm.nih.gov/pubmed/24753036

2014

Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients.
Retèl VP, Steuten LM, Mewes JC, van Harten WH.
Value Health. 2014 Nov;17
https://www.ncbi.nlm.nih.gov/pubmed/27202291

Budget Impact Analysis of a Return-To-Work Intervention for Cancer Patients Shows Hospitals Bear the Costs, for Society to Enjoy the Benefits.
Mewes JC, Steuten LM, de Boer A, Frings-Dresen M, IJzerman MJ, van Harten W.
Value Health. 2014 Nov
https://www.ncbi.nlm.nih.gov/pubmed/27202201

2012

Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review.
Mewes JC, Steuten LM, Ijzerman MJ, van Harten WH.
Oncologist. 2012;17(12)
https://www.ncbi.nlm.nih.gov/pubmed/22982580